A major challenge is to find therapeutic solutions that can quickly reach affected patients to reduce the morbidity and mortality of the highly contagious SARS-CoV2. The aim of this study is to identify antiviral drugs that interfere with the SARS-CoV2 infection cycle by blocking two different phases of viral entry into human cells. We are trying to accelerate the discovery of antiviral drugs through the drug re-profiling strategy that allows existing drugs to be reassigned for treating COVID-19.